(MedPage Today) — DENVER — Two drug candidates to expand oral therapy options for psoriasis had similar and consistent performances in separate phase III clinical trials reported here.
The allosteric TYK2 inhibitor zasocitinib achieved at…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
